Predicted to enable identical protein binding activity. Predicted to contribute to molybdopterin synthase activity. Predicted to be involved in Mo-molybdopterin cofactor biosynthetic process. Predicted to be located in nuclear speck. Predicted to be part of molybdopterin synthase complex. Predicted to be active in cytosol. Human ortholog(s) of this gene implicated in molybdenum cofactor deficiency type B. Orthologous to human MOCS2 (molybdenum cofactor synthesis 2); PARTICIPATES IN molybdenum cofactor biosynthetic pathway; folate metabolic pathway; INTERACTS WITH (+)-schisandrin B; 2,3,7,8-tetrachlorodibenzodioxine; 3-chloropropane-1,2-diol.
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA
[azoxystrobin co-treated with 2-chloro-N-(4-chlorobiphenyl-2-yl)nicotinamide co-treated with Chlorpyrifos co-treated with glyphosate co-treated with imidacloprid co-treated with Thiabendazole] results in decreased expression of MOCS2 mRNA